Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma

Hepatology

Volumn 52, Issue 1, 2010, Pages 174-182

  Matsuda, Atsushi ^a   Kuno, Atsushi ^a   Kawamoto, Toru ^b   Matsuzaki, Hideki ^a   Irimura, Tatsuro ^c   Ikehara, Yuzuru ^a   Zen, Yoh ^d   Nakanuma, Yasuni ^d   Yamamoto, Masakazu ^e   Ohkohchi, Nobuhiro ^f   Shoda, Junichi ^f   Hirabayashi, Jun ^a   Narimatsu, Hisashi ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b Tsukuba Stomach and Intestinal Hospital   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MARKER; MONOCLONAL ANTIBODY; MUCIN 1; PLANT LECTIN;

ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; INTRAHEPATIC CHOLANGIOCARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIALYLATION; STAINING; WESTERN BLOTTING; WISTERIA; WISTERIA FLORIBUNDA;

ANTIBODIES, MONOCLONAL; BILE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MUCIN-1; PLANT LECTINS; PROTEIN ARRAY ANALYSIS; RECEPTORS, N-ACETYLGLUCOSAMINE; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 77954228152     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23654     Document Type: Article

References (41)

1. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002;17:1049-1055. (Pubitemid 35013958)
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. HEPATOLOGY 2001;33:1353-1357. (Pubitemid 32496970)
3. Taylar-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-820.
4. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-1314.
5. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol 2009;69:259-270.
6. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WMC, Taylor-Rbinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51:VI1-VI9.
7. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004;101:1609-1615.
8. Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma-the influence of sampling time and hepatolithiasis. Hepatogastroenterology 2002;49:616-620.
9. Ker CG, Chen JS, Lee KT, Sheen PC, Wu CC. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol 1991;6:505-508.
10. Sauri JC, Joly-Pharaboz MO, Pernas P, Henry L, Ponchon T, Madjar JJ. Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures. HEPATOLOGY 1990;12:747-752. (Pubitemid 20349261)
11. Kurzawinski T, Deery A, Dooley J, Dick R, Hobbs K, Davidson B. A prospective controlled study comparing brush and bile exfoliative cytology for diagnosing bile duct strictures. Gut 1992;33:1675-1677.
12. Kurzawinski TR, Deery A, Dooley JS, Dick R, Hobbs KE, Davidson BR. A prospective study of biliary cytology in 100 patients with bile duct strictures. HEPATOLOGY 1993;18:1399-1403. (Pubitemid 23348428)
13. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002;99:10231-10233.
14. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res 1996;56:2237-2244. (Pubitemid 26154066)
15. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990;99:508-518. (Pubitemid 20219108)
16. Nakagawa T, Miyashi E, Yakushijin T, Hiramatsu N, Igura T, Hayashi N, et al. Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients. J Proteome Res 2008;7:2222-2233.
17. Ito H, Kuno A, Sawaki H, Sogabe M, Ozaki H, Tanaka Y, et al. Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. J Proteome Res 2009;8:1358-1367.
18. Hirabayashi J. Concept, strategy and realization of lectin-based glycan profiling. J Biochem 2008;144:139-147.
19. Kuno A, Uchiyama N, Kuno-Koseki S, Ebe Y, Takashima S, Yamada M, et al. Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods 2005;2:851-856. (Pubitemid 41741536)
20. Uchiyama N, Kuno A, Tateno H, Kubo Y, Mizuno M, Noguchi M, et al. Optimization of evanescent-field fluorescence-assisted lectin microarray for high-sensitivity detection of monovalent oligosaccharides and glycoproteins. Proteomics 2008;8:3042-3050.
21. Matsuda A, Kuno A, Ishida Y, Kawamoto T, Shoda J, Hirabayashi J. Development of an all-in-one technology for glycan profiling targeting formalin-embedded tissue sections. Biochem Biophys Res Commun 2008;370:259-263.
22. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1999;1473:67-95.
23. Kuno A, Itakura Y, Toyoda M, Takahashi Y, Yamada M, Umezawa A, et al. Development of a data-mining system for differential profiling of cell glycoproteins based on lectin microarray. J Proteomics Bioinform 2008;1:061-067.
24. Zweig MH. Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577. (Pubitemid 23118304)
25. Yamamoto M, Bhavanandan VP, Nakamori S, Irimura T. A novel monoclonal antibody specific for sialylated MUC1 mucin. Jpn J Cancer Res 1996;87:488-496. (Pubitemid 26182319)
26. Takeuchi H, Kato K, Denda-Nagai K, Hanisch FG, Clausen H, Irimura T. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. J Immunol Methods 2002;270:199-209.
27. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006;281:29797-29806.
28. Yamazaki K, Powers SP, LaRusso NF. Biliary proteins: assessment of quantitative techniques and comparison in gallstone and nongallstone subjects. J Lipid Res 1988;29:1055-1063.
29. Kuno A, Kato Y, Matsuda A, Kato-Kaneko M, Ito H, Amano K, et al. Focused differential glycan analysis with the platform antibody-assisted lectin profiling (ALP) for glycan-related biomarker verification. Mol Cell Proteomics 2009;8:99-108.
30. Ikehara Y, Sato T, Niwa T, Nakamura S, Gotoh M, Ikehara SK, et al. Apical Golgi localization of N,N′-diacetyllactosediamine synthase, β4GalNAc-T3, is responsible for LacdiNAc expression on gastric mucosa. Glycobiology 2006;16:777-785.
31. Kawamoto T, Shoda J, Miyahara N, Suzuki H, Furukawa M, Todoroki T, et al. Expression of MUC1 mucins in the subserosal layer correlates with post-surgical prognosis of pathological tumor stage 2 carcinoma of the gall-bladder. Clin Cancer Res 2001;7:1333-1342.
32. Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS, et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. HEPATOLOGY 1999;30:1347-1355.
33. Bamrungphon W, Prempracha N, Bunchu N, Rangdaeng S, Sandhu T, Srisukho S, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007;247:301-308. (Pubitemid 46240619)
34. Narimatsu H, Sawaki H, Kuno A, Kaji H, Ito H, Ikehara Y. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 2010;277:95-105.
35. Matsuzaki Y, Osuga T, Saito Y, Chuganji Y, Tanaka N, Shoda J, et al. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994;106:1032-1041. (Pubitemid 24109291)
36. Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, et al. Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients. Clin Cancer Res 2005;11:3799-3084.
37. Maeda T, Adachi E, Kajiyama K, Sugimachi S, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analyses of clinicopathologic features. Hum Pathol 1995;26:956-964.
38. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 1988;12:187-197.
39. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-1461.
40. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-1024.
41. Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, et al. Identification of novel candidate tumor marker genes for intrahepatic cholangiocarcinoma. J Hepatol 2008;49:207-216.